Home Cart Sign in  
Chemical Structure| 871700-17-3 Chemical Structure| 871700-17-3

Structure of Trametinib
CAS No.: 871700-17-3

Chemical Structure| 871700-17-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50 values of about 2 nM. Trametinib activates autophagy and induces apoptosis.

Synonyms: JTP-74057; GSK1120212

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Trametinib

CAS No. :871700-17-3
Formula : C26H23FIN5O4
M.W : 615.39
SMILES Code : CC(NC1=CC=CC(N(C(C(C(N2C3CC3)=O)=C(NC4=CC=C(I)C=C4F)N5C)=C(C)C5=O)C2=O)=C1)=O
Synonyms :
JTP-74057; GSK1120212
MDL No. :MFCD17215075
InChI Key :LIRYPHYGHXZJBZ-UHFFFAOYSA-N
Pubchem ID :11707110

Safety of Trametinib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H317-H361-H372
Precautionary Statements:P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P201-P202-P281-P308+P313-P405-P501-P260-P264-P270-P314-P501

Related Pathways of Trametinib

MAPK

Isoform Comparison

Biological Activity

Target
  • MEK2

    MEK2, IC50:1.8 nM

  • MEK1

    MEK1, IC50:0.92 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
CRC cells 25 nM 5 days To evaluate the effect of Trametinib in combination with JQ1 on CRC cell colony formation, results showed that the combination almost completely abolished the colony-forming ability of CRC cells PMC5368030
SW480 cells 50 nM 2 days To evaluate the effect of Trametinib in combination with JQ1 on MYC protein expression in SW480 cells, results showed that the combination significantly reduced MYC protein levels PMC5368030
BBN963 cells 100 µM 72 h To evaluate the apoptosis-inducing effect of Trametinib on BBN963 cells, results showed that Trametinib alone led to increased numbers of cells in late apoptosis. PMC11297265
BBN963 cells 100 µM 72 h To evaluate the apoptosis-inducing effect of combined Rosiglitazone and Trametinib treatment on BBN963 cells, results showed that the combined treatment further increased the percentage of cells in both early and late apoptosis. PMC11297265
KRAS-mutant mouse lung cancer cells 100 nM 72 h To evaluate the effect of Trametinib on the growth of KRAS-mutant mouse lung cancer cells, results showed that Trametinib significantly inhibited cell growth. PMC11031964
KRAS-mutant human lung cancer cells 500 nM 72 h To evaluate the effect of Trametinib on the growth of KRAS-mutant human lung cancer cells, results showed that Trametinib significantly inhibited cell growth. PMC11031964
KRAS-wild type human lung cancer cells 500 nM 72 h To evaluate the effect of Trametinib on the growth of KRAS-wild type human lung cancer cells, results showed that Trametinib did not significantly affect cell growth. PMC11031964
TBP primary melanoma cells 1 nM 10 days To evaluate the effect of Trametinib on melanoma spheroids, results showed that Trametinib inhibited spheroid growth. PMC10478295
S462 cells 200 nM 24 h To evaluate the anti-proliferative activity of Trametinib on MPNST cells, results showed that Trametinib combined with Palbociclib significantly reduced RB1 phosphorylation levels. PMC10528807

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Subcutaneous CRC xenograft model Oral 0.5 mg/kg or 1 mg/kg Once daily for 14 days To evaluate the effect of Trametinib in combination with JQ1 on subcutaneous CRC xenograft tumors, results showed that the combination significantly reduced tumor volume PMC5368030
Mice BBN-induced BASQ bladder cancer model Oral 0.3 mg/kg Daily for one month To evaluate the effect of Trametinib alone on BBN-induced BASQ tumors, results showed that Trametinib alone reduced tumor proliferation but did not completely eliminate tumors. PMC11297265
Mouse KRAS-mutant lung cancer model Oral 1 mg/kg 5 times a week for 30 days To evaluate the effect of Trametinib on tumor growth in KRAS-mutant lung cancer mouse models, results showed that Trametinib significantly reduced tumor volume. PMC11031964
Mice Pancreatic cancer model Oral 1 mg/kg Four consecutive days, followed by 3 days off treatment To evaluate the therapeutic effect of Trametinib in a pancreatic cancer model PMC9701143
Mice TBP melanoma model Oral 1 mg/kg Daily for 5 weeks To evaluate the therapeutic effect of Trametinib on melanoma, results showed that Trametinib significantly inhibited tumor growth and delayed the onset of resistance. PMC10478295
NOD-SCID mice QGP-1 xenograft model Oral 1 mg/kg Twice a week for 2 weeks To evaluate the effect of Trametinib on the invasion capability of PTEN-knockdown QGP-1 xenograft tumors, results showed that Trametinib significantly suppressed tumor invasion. PMC9639322
Mice MPNST PDX model Oral 0.075 mg/kg Once daily for 5 days, off for 2 days To evaluate the anti-tumor activity of Trametinib combined with Ribociclib on MPNST PDX models, results showed that the combination therapy significantly slowed tumor growth. PMC10528807

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03225664 Lung Diseases Due to External ... More >>Agents Non-Small Cell Lung Cancer Less << Phase 1 Phase 2 Recruiting May 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations       CR_Study_Registration@mdanderson.org Less <<
NCT02872259 Melanoma Phase 1 Phase 2 Recruiting March 2020 Norway ... More >> Haukeland University Hospital Recruiting Bergen, Norway, 5021 Contact: Oddbjørn Straume, MD, PhD       oddbjorn.straume@helse-bergen.no    Akershus Univerisity Hospital Not yet recruiting Lørenskog, Norway, 1478 Contact: Jürgen Geisler, MD, PhD       Jurgen.geisler@ahus.no    Oslo University Hospital, Radiumhospitalet Recruiting Oslo, Norway, 0424 Contact: Marta Nyakas, MD, PhD       marta.nyakas@ous.no    University Hospital of North Norway Recruiting Tromsø, Norway, 9038 Contact: Anita Amundsen, MD       Anita.amundsen@unn.no    St. Olavs Hospital Recruiting Trondheim, Norway, 7006 Contact: Jarle Karlsen, MD       Jarle.Karlsen@stolav.no Less <<
NCT02039947 Melanoma and Brain Metastases Phase 2 Completed - -
NCT01721603 - Terminated(Low accrual) - -
NCT02684058 Diffuse Astrocytoma ... More >> Anaplastic Astrocytoma Astrocytoma Oligodendroglioma, Childhood Anaplastic Oligodendroglioma Glioblastoma Pilocytic Astrocytoma Giant Cell Astrocytoma Pleomorphic Xanthoastrocytoma Anaplastic Pleomorphic Xanthoastrocytoma Angiocentric Glioma Chordoid Glioma of Third Ventricle Gangliocytoma Ganglioglioma Anaplastic Ganglioglioma Dysplastic Gangliocytoma of Cerebrellum Desmoplastic Infantile Astrocytoma and Ganglioglioma Papillary Glioneuronal Tumor Rosette-forming Glioneurona Tumor Central Neurocytoma Extraventricular Neurocytoma Cerebellar Iponeurocytoma Less << Phase 2 Recruiting September 13, 2024 -
NCT01721603 BRAFV600E Melanoma Patients Phase 2 Terminated(Low accrual) - United States, California ... More >> University of San Francisco, California San Francisco, California, United States, 94115 Less <<
NCT01902173 Adult Solid Neoplasm ... More >> Recurrent Colon Carcinoma Recurrent Melanoma Recurrent Ovarian Carcinoma Stage IIIC Colon Cancer Stage IIIC Ovarian Cancer Stage IIIC Skin Melanoma Stage IV Skin Melanoma Less << Phase 1 Phase 2 Suspended(Temporarily stopped ... More >>for assessment. Contact ctsucontact@westat.com for specifics) Less << - United States, California ... More >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 California Pacific Medical Center-Pacific Campus San Francisco, California, United States, 94115 UCSF Medical Center-Mount Zion San Francisco, California, United States, 94115 United States, Colorado University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States, 80045 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Oregon Clackamas Radiation Oncology Center Clackamas, Oregon, United States, 97015 Providence Milwaukie Hospital Milwaukie, Oregon, United States, 97222 Providence Newberg Medical Center Newberg, Oregon, United States, 97132 Providence Willamette Falls Medical Center Oregon City, Oregon, United States, 97045 Providence Portland Medical Center Portland, Oregon, United States, 97213 Providence Saint Vincent Medical Center Portland, Oregon, United States, 97225 Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Washington PeaceHealth Southwest Medical Center Vancouver, Washington, United States, 98664 Less <<
NCT02382549 Melanoma Phase 1 Phase 2 Recruiting June 2020 United States, Virginia ... More >> Cancer Center at the University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Less <<
NCT03704688 Non Small Cell Lung Cancer ... More >> KRAS Gene Mutation Less << Phase 1 Phase 2 Recruiting April 2021 United States, New Jersey ... More >> Memoral Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Kathryn Arbour, MD    646-449-1775       United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Kathryn Arbour, MD    646-449-1775       Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Kathryn Arbour, MD    646-449-1775       Memorial Sloan Kettering @ Rockville Recruiting Rockville Centre, New York, United States, 11570 Contact: Kathryn Arbour, MD    646-449-1775 Less <<
NCT02281760 BRAF V600E Mutation Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01248858 Cancer Phase 1 Terminated(The reason for term... More >>ination was lack of tolerability and efficacy of the combination treatment) Less << - United States, North Carolina ... More >> GSK Investigational Site Chapel Hill, North Carolina, United States, 27599-7305 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 Canada, Ontario GSK Investigational Site Toronto, Ontario, Canada, M5G 2M9 Italy GSK Investigational Site Milano, Lombardia, Italy, 20132 Less <<
NCT01912625 KRAS Activating Mutation ... More >> Recurrent Non-Small Cell Lung Carcinoma Stage III Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Less << Phase 1 Active, not recruiting - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Less <<
NCT01584648 Melanoma Phase 3 Active, not recruiting October 15, 2018 -
NCT01584648 - Active, not recruiting - -
NCT02152995 BRAF Gene Mutation ... More >> Poorly Differentiated Thyroid Gland Carcinoma RAS Family Gene Mutation Recurrent Thyroid Gland Carcinoma Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 Less << Phase 2 Recruiting - United States, New York ... More >> Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Alan L. Ho    646-888-4235    hoa@mskcc.org    Principal Investigator: Alan L. Ho Less <<
NCT01336634 Cancer Phase 2 Active, not recruiting December 1, 2020 -
NCT02416232 - - - France ... More >> GSK Investigational Site Amiens Cedex, France, 80054 GSK Investigational Site Angers, France, 49100 GSK Investigational Site Bayonne cedex, France, 64109 GSK Investigational Site Besancon cedex, France, 25030 GSK Investigational Site Bobigny, France, 93000 GSK Investigational Site Bordeaux, France, 33075 GSK Investigational Site Boulogne-Billancourt, France, 92100 GSK Investigational Site Brest cedex, France, 29609 GSK Investigational Site Caen Cedex 9, France, 14033 GSK Investigational Site Chambray-Les-Tours, France, 37170 GSK Investigational Site Clermont-Ferrand cedex 1, France, 63003 GSK Investigational Site Creteil, France, 94010 GSK Investigational Site Dijon Cedex, France, 21079 GSK Investigational Site Grenoble cedex 9, France, 38043 GSK Investigational Site La Rochelle cedex 1, France, 17019 GSK Investigational Site Le Havre, France, 76083 GSK Investigational Site Le Mans, France, 72000 GSK Investigational Site Lille, France, 59037 GSK Investigational Site Limoges cedex, France, 87042 GSK Investigational Site Lorient, France, 56322 GSK Investigational Site Lyon Cedex 08, France, 69373 GSK Investigational Site Marseille Cedex 5, France, 13385 GSK Investigational Site Montpellier cedex 5, France, 34295 GSK Investigational Site Montpellier Cedex 5, France, 34298 GSK Investigational Site Mulhouse, France, 68100 GSK Investigational Site Nantes Cedex 1, France, 44093 GSK Investigational Site Nice, France, 06202 GSK Investigational Site Nimes, France, 30029 cedex 9 GSK Investigational Site Orleans Cedex 2, France, 45067 GSK Investigational Site Paris Cedex 10, France, 75475 GSK Investigational Site Paris, France, 75006 GSK Investigational Site Pau, France, 64000 GSK Investigational Site Pierre-Benite cedex, France, 69495 GSK Investigational Site Poitiers, France, 86021 GSK Investigational Site Pringy Cedex, France, 74374 GSK Investigational Site Reims Cedex, France, 51092 GSK Investigational Site Rennes Cedex, France, 35042 GSK Investigational Site Rouen, France, 76031 GSK Investigational Site Saint-Pierre, France, 97448 GSK Investigational Site Saint-Priest en Jarez, France, 42270 GSK Investigational Site Strasbourg Cedex, France, 67091 GSK Investigational Site Thionville, France, 57126 Cedex 1 GSK Investigational Site Toulouse Cedex 9, France, 31059 GSK Investigational Site Valence Cedex 9, France, 26953 GSK Investigational Site Vandoeuvre-Les-Nancy, France, 54511 GSK Investigational Site Villejuif cedex, France, 94805 Less <<
NCT02910700 BRAF Gene Mutation ... More >> BRAF wt Allele Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Less << Phase 2 Recruiting December 31, 2021 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Hussein A. Tawbi    713-792-2921       Principal Investigator: Hussein A. Tawbi Less <<
NCT01943864 Cancer Phase 2 Completed - Japan ... More >> GSK Investigational Site Chiba, Japan, 277-8577 GSK Investigational Site Osaka, Japan, 537-8511 GSK Investigational Site Shizuoka, Japan, 411-8777 GSK Investigational Site Tokyo, Japan, 104-0045 GSK Investigational Site Tokyo, Japan, 181-8611 Less <<
NCT02357732 Metastatic Melanoma Phase 1 Withdrawn(PI decided not to pr... More >>oceed) Less << - -
NCT01336634 - Active, not recruiting - -
NCT01723202 Follicular Thyroid Cancer ... More >> Insular Thyroid Cancer Papillary Thyroid Cancer Recurrent Thyroid Cancer Less << Phase 2 Active, not recruiting December 31, 2019 United States, California ... More >> University of California, San Diego San Diego, California, United States, 92093-0698 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Massachusetts Massachusetts General Hospital, Harvard Medical School Boston, Massachusetts, United States, 02114 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Texas The University of Texas-MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02367859 Ameloblastoma ... More >> BRAF Gene Mutation Less << Phase 2 Recruiting August 2020 United States, California ... More >> Stanford University, School of Medicine Recruiting Stanford, California, United States, 94305 Contact: Elizabeth Winters    650-721-6509    ewinters@stanford.edu    Principal Investigator: Alexander D. Colevas          Sub-Investigator: Jonathan Pollack          Sub-Investigator: Davud Sirjani          Sub-Investigator: Robert West Less <<
NCT02027961 Melanoma Phase 1 Phase 2 Completed - United States, Arizona ... More >> Research Site Scottsdale, Arizona, United States, 85258 United States, California Research Site Los Angeles, California, United States, 90095 Research Site San Francisco, California, United States, 94143 United States, Florida Research Site Miami Beach, Florida, United States, 33140 United States, Illinois Research Site Chicago, Illinois, United States, 60611 United States, Massachusetts Research Site Boston, Massachusetts, United States, 02114 United States, Missouri Research Site Saint Louis, Missouri, United States, 63110 Canada, Ontario Research Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Research Site Montreal, Quebec, Canada, H3A 1A1 France Research Site Villejuif cedex, France, 94805 Italy Research Site Napoli, Italy, 80131 Less <<
NCT01943864 - Completed - -
NCT01658553 Cancer PHASE1 COMPLETED 2014-04-05 GSK Investigational Site, San ... More >>Antonio, Texas, 78229, United States|GSK Investigational Site, Salt Lake City, Utah, 84112, United States Less <<
NCT02399943 Colorectal Cancer ... More >> KRAS Wildtype NRAS Wildtype BRAF Wildtype Less << Phase 2 Recruiting December 2020 Canada, Ontario ... More >> Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada Contact: Philippe Bedard, M.D.    416-946-4534    Philippe.Bedard@uhn.ca Less <<
NCT02143050 Melanoma Phase 1 Phase 2 Recruiting June 2020 United States, Kentucky ... More >> James Graham Brown Cancer Center-Universityof Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Jason A Chesney, MD, PhD    502-562-3429    jason.chesney@louisville.edu    Contact: Christina LaDuke    502-217-5205    christy.laduke@louisville.edu    Sub-Investigator: Donald M Miller, MD, PhD          Sub-Investigator: Kelly M McMasters, MD, PhD          Sub-Investigator: Sucheta Telang, MD          James Graham Brown Cancer Center Recruiting Louisville, Kentucky, United States, 40202 Contact: Karen Carter, BSN    502-562-3690    kmcart05@louisville.edu    Contact: Christina LaDuke, BS    502-217-5205    christi.laduke@louisville.edu Less <<
NCT02065063 Cancer Phase 1 Completed - United States, Massachusetts ... More >> GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030-4009 Less <<
NCT01979523 Recurrent Uveal Melanoma ... More >> Stage IV Uveal Melanoma AJCC v7 Less << Phase 2 Completed - United States, Georgia ... More >> Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, New York Columbia University/Herbert Irving Cancer Center New York, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 France Institut Curie Paris Paris, France, 75005 United Kingdom The University of Liverpool Liverpool, United Kingdom, L69 3GA Less <<
NCT02196181 BRAF V600E Mutation Present ... More >> BRAF V600K Mutation Present Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Melanoma Less << Phase 2 Recruiting - -
NCT02314143 Melanoma Phase 2 Completed - France ... More >> GSK Investigational Site Bordeaux, France, 33075 GSK Investigational Site Marseille cedex 5, France, 13385 GSK Investigational Site Reims Cedex, France, 51092 GSK Investigational Site Rennes Cedex, France, 35042 GSK Investigational Site Villejuif cedex, France, 94805 Spain GSK Investigational Site Barcelona, Spain, 08036 GSK Investigational Site Madrid, Spain, 28041 Less <<
NCT02016729 Advanced Malignancy ... More >> Cancer Oncology Oncology Patients Acute Myeloid Leukemia Less << Phase 1 Completed - United States, Alabama ... More >> Research Site Birmingham, Alabama, United States, 35294 United States, New York Research Site Buffalo, New York, United States, 14263 United States, North Carolina Research Site Charlotte, North Carolina, United States, 28204 United States, Utah Research Site Salt Lake City, Utah, United States, 84112 United States, Washington Research Site Seattle, Washington, United States, 98101 Less <<
NCT03543306 Cancer Lung C... More >>ancer Metastatic BRAF V600E Less << Phase 2 Recruiting June 30, 2022 Korea, Republic of ... More >> Asan Medical Center Recruiting Seoul, Korea, Republic of, 138-736 Contact: Sang-We Kim, M.D.    82-2-3010-3215    swkim@amc.seoul.kr    Principal Investigator: Sang-We Kim, M.D. Less <<
NCT03026517 Melanoma Phase 1 Recruiting January 2020 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Keith Flaherty, MD    617-724-4800       United States, New York Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Paul Chapman, MD    646-888-4162       Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Paul Chapman, MD    646-888-4162       Contact: Michael Postow, MD    646-888-4589       Principal Investigator: Paul Chapman, MD Less <<
NCT01935973 Endometrial Adenocarcinoma ... More >> Endometrial Clear Cell Adenocarcinoma Endometrial Mixed Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Undifferentiated Carcinoma Recurrent Uterine Corpus Carcinoma Less << Phase 1 Active, not recruiting - -
NCT02231775 BRAF V600E Mutation Present ... More >> BRAF V600K Mutation Present Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Less << Phase 2 Recruiting October 31, 2019 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jennifer Wargo    713-745-1553       Principal Investigator: Jennifer Wargo Less <<
NCT01938443 Cancer Phase 1 Completed - France ... More >> GSK Investigational Site Villejuif Cedex, France, 94805 United Kingdom GSK Investigational Site London, United Kingdom, W12 0HS GSK Investigational Site London, United Kingdom, W1G 6AD GSK Investigational Site Newcastle upon Tyne, United Kingdom, NE7 7DN Less <<
NCT03087071 Colorectal Cancer Phase 2 Recruiting December 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       evilar@mdanderson.org Less <<
NCT02967692 Melanoma Phase 3 Recruiting February 13, 2020 -
NCT01907815 Recurrent Adult Acute Myeloid ... More >>Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 2 Terminated(Lack of efficacy.) - United States, Illinois ... More >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02079740 Advanced Malignant Solid Neopl... More >>asm KRAS Gene Mutation Metastatic Malignant Solid Neoplasm NRAS Gene Mutation Recurrent Colorectal Carcinoma Recurrent Lung Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Pancreatic Carcinoma Stage III Colorectal Cancer AJCC v7 Stage III Lung Cancer AJCC v7 Stage III Pancreatic Cancer AJCC v6 and v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IV Lung Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Unresectable Malignant Neoplasm Less << Phase 1 Phase 2 Recruiting - United States, Massachusetts ... More >> Massachusetts General Hospital Cancer Center Suspended Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Ryan B. Corcoran    877-726-5130       Principal Investigator: Ryan B. Corcoran Less <<
NCT01907815 - Terminated(Lack of efficacy.) - -
NCT02258607 Relapsed Metastatic KRAS-Mutat... More >>ed Non-Small Cell Lung Cancer Less << Phase 1 Terminated - United States, California ... More >> Duarte, California, United States Sacramento, California, United States United States, Massachusetts Boston, Massachusetts, United States United States, Virginia Fairfax, Virginia, United States United States, Washington Spokane, Washington, United States Less <<
NCT02230553 Colorectal Cancer Phase 1 Phase 2 Recruiting December 2019 Netherlands ... More >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066CX Contact: N HM Steeghs, MD, PhD    0031205122446    n.steeghs@nki.nl Less <<
NCT02642042 KRAS Gene Mutation ... More >> Recurrent Non-Small Cell Lung Carcinoma Stage IV Non-Small Cell Lung Cancer AJCC v7 Less << Phase 2 Active, not recruiting October 15, 2020 -
NCT03317119 RAS Family Gene Mutation ... More >> Stage III Colon Cancer AJCC v7 Stage III Colorectal Cancer AJCC v7 Stage III Rectal Cancer AJCC v7 Stage IIIA Colon Cancer AJCC v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIA Rectal Cancer AJCC v7 Stage IIIB Colon Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIB Rectal Cancer AJCC v7 Stage IIIC Colon Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IIIC Rectal Cancer AJCC v7 Stage IV Colon Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IV Rectal Cancer AJCC v7 Stage IVA Colon Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVA Rectal Cancer AJCC v7 Stage IVB Colon Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Stage IVB Rectal Cancer AJCC v7 Less << Phase 1 Recruiting December 2019 United States, California ... More >> City of Hope Corona Recruiting Corona, California, United States, 92879 Contact: Cheryl Corpus    626-256-4673 ext 81529       Principal Investigator: Misagh Karimi, MD          City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Marwan Fakih, MD    626-256-4673    mfakih@coh.org    Principal Investigator: Marwan Fakih, MD          City of Hope Antelope Valley Recruiting Lancaster, California, United States, 93534 Contact: Regan Johnson    626-256-4673 ext 25648       Principal Investigator: Mohammad Fekrazad, MD          City of Hope Mission Hills Recruiting Mission Hills, California, United States, 91345 Contact: Amy Shousha    626-256-4673 ext 81865       Principal Investigator: Suzy Melkonian, MD          City of Hope Rancho Cucamonga Recruiting Rancho Cucamonga, California, United States, 91730 Contact: Valerie Estala    626-256-4673 ext 81699       Principal Investigator: Behnam Ebrahimi, MD          City of Hope South Pasadena Recruiting South Pasadena, California, United States, 91030 Contact: Odessa Rodriguez    626-256-4673 ext 81409       Principal Investigator: Christina Yeon, MD          City of Hope West Covina Recruiting West Covina, California, United States, 91790 Contact: Meizi Zheng    626-256-4673 ext 81336       Principal Investigator: Gargi Upadhyaya, MD Less <<
NCT01989598 Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less << Phase 2 Active, not recruiting - Canada, Alberta ... More >> Foothills Hospital Calgary, Alberta, Canada, T2N 2T9 Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario Kingston Health Sciences Centre Kingston, Ontario, Canada, K7L 2V7 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT01989585 BRAF V600E Mutation Present ... More >> BRAF V600K Mutation Present Metastatic Melanoma Solid Neoplasm Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Less << Phase 1 Phase 2 Recruiting - United States, California ... More >> University of California Davis Comprehensive Cancer Center Suspended Sacramento, California, United States, 95817 United States, Massachusetts Massachusetts General Hospital Cancer Center Withdrawn Boston, Massachusetts, United States, 02114 United States, Missouri Siteman Cancer Center at West County Hospital Suspended Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Suspended Saint Louis, Missouri, United States, 63110 Siteman Cancer Center-South County Suspended Saint Louis, Missouri, United States, 63129 Siteman Cancer Center at Christian Hospital Suspended Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Suspended Saint Peters, Missouri, United States, 63376 United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact    732-235-8675       Principal Investigator: Janice M. Mehnert          United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact    888-275-3853       Principal Investigator: James L. Abbruzzese          United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu    Principal Investigator: Kari L. Kendra          United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact    877-312-3961       Principal Investigator: Michael A. Davies Less <<
NCT03754179 Melanoma Phase 1 Phase 2 Recruiting December 1, 2020 Belgium ... More >> UZ Brussel Recruiting Jette, Brabant, Belgium, 1090 Contact: Bart Neyns, Phd,Md    0032(0)2477 64 15    bart.neyns@uzbrussel.be    Principal Investigator: Bart Neyns, Phd,Md Less <<
NCT02124772 Cancer Phase 1 Recruiting October 15, 2020 United States, Arizona ... More >> Novartis Investigative Site Recruiting Phoenix, Arizona, United States, 85016-7710 United States, California Novartis Investigative Site Recruiting San Francisco, California, United States United States, Maryland Novartis Investigative Site Recruiting Baltimore, Maryland, United States, 21287 United States, Massachusetts Novartis Investigative Site Recruiting Boston, Massachusetts, United States, 02115 United States, Minnesota Novartis Investigative Site Recruiting Minneapolis, Minnesota, United States, 55455 United States, New York Novartis Investigative Site Recruiting New York, New York, United States, 10065 United States, Ohio Novartis Investigative Site Recruiting Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Novartis Investigative Site Recruiting Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Novartis Investigative Site Recruiting Memphis, Tennessee, United States, 38105-3678 United States, Washington Novartis Investigative Site Recruiting DC, Washington, United States, DC 20010 Australia, New South Wales Novartis Investigative Site Recruiting Westmead, New South Wales, Australia, 2145 Canada, Ontario Novartis Investigative Site Recruiting Toronto, Ontario, Canada, M5G 1X8 France Novartis Investigative Site Recruiting Paris Cedex 05, France, 75248 Novartis Investigative Site Recruiting Villejuif Cedex, France, 94805 United Kingdom Novartis Investigative Site Recruiting Sutton, Surrey, United Kingdom, SM2 5PT Novartis Investigative Site Recruiting London, United Kingdom, WC1N 3JH Less <<
NCT01978236 - Terminated(This study was term... More >>inated due to the limited enrollment.) Less << - -
NCT02292732 Cancer Phase 1 Withdrawn May 2017 -
NCT02097225 BRAF V600E Mutation Present ... More >> BRAF V600K Mutation Present Metastatic Malignant Solid Neoplasm Metastatic Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Solid Neoplasm Less << Phase 1 Recruiting - United States, Massachusetts ... More >> Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Ryan J. Sullivan    617-724-4000    rsullivan7@partners.org    Principal Investigator: Ryan J. Sullivan          Dana-Farber Cancer Institute Suspended Boston, Massachusetts, United States, 02215 Less <<
NCT01978236 Melanoma and Brain Metastases Phase 2 Terminated(This study was term... More >>inated due to the limited enrollment.) Less << - United States, Pennsylvania ... More >> GSK Investigational Site Pittsburgh, Pennsylvania, United States, 15232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 Australia, New South Wales GSK Investigational Site North Sydney, New South Wales, Australia, 2060 Less <<
NCT02439411 Malignant Melanoma Stage IV|Ma... More >>lignant Melanoma Stage IIIc Less << COMPLETED 2025-09-16 Complejo Hospitalario Torrecár... More >>denas, Almeria, Almería, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Baleares, Spain|Instituto Catalán de Oncología Badalona/Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Instituto Catalán de Oncología L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain|Corporació Sanitaria Parc Taulí de Sabadell, Sabadell, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Onkologikoa Fundazioa, Donostia, Guipúzcoa, Spain|Complejo Hospitalario Universitario Insular de Canarias, Las Palmas de Gran Canaria, Las Palmas, Spain|Clínica Universidad Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Navarra, Pamplona, Navarra, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital General Universitario de Elche, Elche, Spain|Instituto Catalán de Oncología Girona/Hospital Universitari Dr. Josep Trueta, Girona, Spain|Hospital Universitario San Cecilio, Granada, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitaria La Princesa, Madrid, Spain|Hospital Universitario Gregorio Mara?ón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Complexo Hospitalario Universitario de Ourense, Orense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario de Valme, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain Less <<
NCT02974803 Melanoma Brai... More >>n Metastases Less << Phase 2 Recruiting June 2020 Canada, Nova Scotia ... More >> QEII Health Sciences Centre Recruiting Halifax, Nova Scotia, Canada, B3H 1V7 Contact: Robyn J. Macfarlane    902 473-6106       Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Elaine McWhirter    905 387-9495 ext 64609       Odette Cancer Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Teresa M. Petrella    416 480-4662       University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Anna Spreafico    416 946-4501 ext 4012       Canada, Quebec Centre hospitalier universitaire de Sherbrooke Recruiting Sherbrooke, Quebec, Canada, J1H 5N4 Contact: David Mathieu    819 346-1110 ext 14887       Canada, Saskatchewan Saskatoon Cancer Centre Recruiting Saskatoon, Saskatchewan, Canada, S7N 4H4 Contact: Vijayananda Kundapur    306 655-2740 Less <<
NCT02034110 Cancer Phase 2 Active, not recruiting June 29, 2020 -
NCT01767454 Solid Tumours Phase 1 Completed - United States, California ... More >> GSK Investigational Site Los Angeles, California, United States, 90025 GSK Investigational Site San Francisco, California, United States, 94115 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02215 United States, Missouri GSK Investigational Site Saint Louis, Missouri, United States, 63110 United States, New York GSK Investigational Site New York, New York, United States, 10065 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 Less <<
NCT03091257 Multiple Myeloma Phase 1 Recruiting December 2021 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Noopur S. Raje, MD    617-726-3810       Principal Investigator: Noopur S. Raje, MD          United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Jeffery Zonder, MD    313-576-8673    zonderj@karmanos.org    Principal Investigator: Jeffery Zonder, MD Less <<
NCT01725100 Cancer Phase 1 Completed - United States, Arizona ... More >> GSK Investigational Site Goodyear, Arizona, United States, 85338 GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, Florida GSK Investigational Site Sarasota, Florida, United States, 34232 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 Less <<
NCT02296112 Recurrent Melanoma ... More >> Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma Less << Phase 2 Recruiting January 2024 United States, District of Col... More >>umbia Georgetown University Medical Center Recruiting Washington, District of Columbia, United States, 20007 Contact: Bridget Haley    202-687-6871       Principal Investigator: Suthee Rapisuwon, MD          United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Keith T Flaherty, MD    617-724-4000    KFLAHERTY@mgh.harvard.edu    Principal Investigator: Keith T. Flaherty, MD          United States, New York Memorial Sloan-Kettering Cancer Center Withdrawn New York, New York, United States, 10021 United States, Pennsylvania University of Pennsylvania Cancer Center Withdrawn Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: B. VICC Clinical Trials Information Program    800-811-8480       Principal Investigator: Douglas B. Johnson, MD          United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Anna Vardeleon    713-794-4274    asreckew@mdanderson.org    Principal Investigator: Michael A. Davies, MD Less <<
NCT02342600 Gastrointestinal Stromal Tumor... More >>s Less << Phase 2 Withdrawn(Supporting company w... More >>ithdrew interest) Less << - -
NCT03148275 Epithelioid Hemangioendothelio... More >>ma Locally Advanced Epithelioid Hemangioendothelioma Metastatic Epithelioid Hemangioendothelioma Less << Phase 2 Recruiting December 31, 2023 -
NCT03272464 Melanoma Phase 1 Recruiting September 30, 2023 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02214 Contact: Keith Flaherty, MD    617-724-4800    KFLAHERTY@mgh.harvard.edu    Principal Investigator: Keith T. Flaherty, MD Less <<
NCT02296996 Malignant Melanoma Phase 2 Active, not recruiting December 2017 Belgium ... More >> UZ Brussel Brussels, Belgium, 1090 Less <<
NCT02538627 Colorectal Cancer ... More >> Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck Less << Phase 1 Terminated(Sponsor decision) - United States, Colorado ... More >> University of Colorado Aurora, Colorado, United States, 80045 United States, Georgia Northside Hospital Sandy Springs, Georgia, United States, 30342 United States, Illinois Northwestern Chicago, Illinois, United States, 60611 United States, Missouri Washington University Saint Louis, Missouri, United States, 63110 United States, Tennessee Vanderbilt Nashville, Tennessee, United States, 37235 Less <<
NCT02292173 Hepatocellular Cancer ... More >> Liver Cancer Less << Phase 1 Active, not recruiting April 2020 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT02672358 Non-Small-Cell Lung Cancer Phase 2 Withdrawn(Company Decision) December 7, 2020 -
NCT02881242 Hormone-Resistant Prostate Can... More >>cer Metastatic Prostate Carcinoma Recurrent Prostate Carcinoma Stage IV Prostate Cancer Less << Phase 2 Recruiting January 31, 2021 United States, California ... More >> UCLA / Jonsson Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90095 Contact: Matthew B. Rettig    310-794-3565    mrettig@mednet.ucla.edu    Principal Investigator: Matthew B. Rettig Less <<
NCT03266159 Solid Tumours Phase 2 Withdrawn(Study withdrawn befo... More >>re active to fully evaluate impact of changing practice in target population.) Less << August 19, 2020 -
NCT03714958 Colorectal Cancer ... More >> Advanced Cancer Metastatic Cancer Less << Phase 1 Not yet recruiting November 2020 -
NCT03386071 - - - -
NCT01682083 - Active, not recruiting - -
NCT02580708 Non-small Cell Lung Cancer Phase 1 Phase 2 Terminated(Discontinued develo... More >>pment of rociletinib in NSCLC. Stopped enrollment of new patients into all studies involving rociletinib.) Less << - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, North Carolina Levine Cancer Institute Charlotte, North Carolina, United States, 28204 United States, Tennessee Tennessee Oncology, PLLC - The Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Virginia Virginia Cancer Specialists Fairfax, Virginia, United States, 22031 Less <<
NCT01682083 Melanoma Phase 3 Active, not recruiting November 30, 2030 -
NCT02083354 Cancer Phase 2 Active, not recruiting December 20, 2019 China, Guangdong ... More >> Novartis Investigative Site Guangzhou, Guangdong, China, 510060 China, Yunnan Novartis Investigative Site Kunming, Yunnan, China, 650106 China, Zhejiang Novartis Investigative Site Hangzhou, Zhejiang, China, 310022 China Novartis Investigative Site Beijing, China, 100036 Hong Kong Novartis Investigative Site Tuen Mun, Hong Kong Korea, Republic of Novartis Investigative Site Seoul, Korea, Republic of, 110-744 Novartis Investigative Site Seoul, Korea, Republic of, 120-752 Taiwan Novartis Investigative Site Kaohsiung, Taiwan, 807 Novartis Investigative Site Taipei, Taiwan, 100 Novartis Investigative Site Taoyuan County, Taiwan, 333 Thailand Novartis Investigative Site Bangkok, Thailand, 10320 Novartis Investigative Site Bangkok, Thailand, 10400 Novartis Investigative Site Songkla, Thailand, 90110 Less <<
NCT02070549 Advanced Malignant Solid Neopl... More >>asm|Metastatic Malignant Neoplasm in the Liver|Metastatic Malignant Solid Neoplasm|Unresectable Solid Neoplasm Less << PHASE1 ACTIVE_NOT_RECRUITING 2025-12-20 University of California Davis... More >> Comprehensive Cancer Center, Sacramento, California, 95817, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT01964924 Estrogen Receptor Negative ... More >> HER2/Neu Negative Invasive Breast Carcinoma Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer Triple-Negative Breast Carcinoma Less << Phase 2 Active, not recruiting - United States, District of Col... More >>umbia MedStar Georgetown University Hospital Washington, D.C., District of Columbia, United States, 20007 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less <<
NCT02015117 Metastatic Malignant Neoplasm ... More >>in the Brain Less << Phase 1 Active, not recruiting - United States, Ohio ... More >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Less <<
NCT03551626 Malignant Melanoma Phase 3 Recruiting October 22, 2021 -
NCT02447939 Melanoma Phase 1 Withdrawn(Change in strategy) December 2018 -
NCT02300935 Melanoma Phase 1 Withdrawn(Study concept was te... More >>rminated.) Less << November 2018 United States, Colorado ... More >> Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Center Sarasota, Florida, United States, 34232 United States, Tennessee Tennessee Oncology PLLC Nashville, Tennessee, United States, 37203 Less <<
NCT01740648 Recurrent Rectal Cancer ... More >> Stage IIA Rectal Cancer Stage IIB Rectal Cancer Stage IIC Rectal Cancer Stage IIIA Rectal Cancer Stage IIIB Rectal Cancer Stage IIIC Rectal Cancer Less << Phase 1 Active, not recruiting December 31, 2022 United States, Missouri ... More >> Washington University Saint Louis, Missouri, United States, 63110 United States, Ohio Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States Less <<
NCT02140840 Multiple Myeloma PHASE2 WITHDRAWN 2025-04-16 University of Arkansas for Med... More >>ical Sciences, Little Rock, Arkansas, 72205, United States Less <<
NCT02428270 Pancreatic Cancer ... More >> Adenocarcinoma Less << Phase 2 Active, not recruiting December 2018 Canada, Ontario ... More >> Juravinski Cancer Center Hamilton, Ontario, Canada, L8V 5C2 London Regional Cancer Centre London, Ontario, Canada The Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT02138292 Melanoma Phase 1 Completed - United States, Texas ... More >> UT Southwestern Medical Center Dallas, Texas, United States, 75390 Less <<
NCT01726738 Stage III Melanoma ... More >> Stage IV Melanoma Unresectable Melanoma BRAF Mutant Melanoma Less << Phase 2 Completed - United States, North Carolina ... More >> Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, North Carolina, United States, 27599 Less <<
NCT03631953 Meningioma Phase 1 Not yet recruiting January 1, 2022 France ... More >> Assistance Publique Hôpitaux de Marseille Not yet recruiting Marseille, France, 13354 Contact: Thomas GRAILLON, PH    491385545 ext +33    thomas.graillon@ap-hm.fr    Contact: Olivier CHINOT, PU-PH    491385545 ext +33    olivier.chinot@ap-hm.fr    Principal Investigator: Thomas GRAILLON, PH Less <<
NCT02705963 Solid Tumors Phase 1 Recruiting May 21, 2019 United States, Michigan ... More >> Karmanos Cancer Institute Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact    313-576-8730       Principal Investigator: Amy M Weise          Henry Ford Hospital Henry Ford Recruiting Detroit, Michigan, United States, 48202 2689 Contact    313-916-8862       Principal Investigator: Ding Wang          United States, Oklahoma University of Oklahoma Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact    405-271-4022       Principal Investigator: Kathleen Moore          Belgium Novartis Investigative Site Recruiting Edegem, Belgium, 2650 Novartis Investigative Site Recruiting Namur, Belgium, 5000 Novartis Investigative Site Recruiting Wilrijk, Belgium, 2610 Netherlands Novartis Investigative Site Recruiting Maastricht, Netherlands, 6202AZ Spain Novartis Investigative Site Recruiting Santiago de Compostela, Galicia, Spain, 15706 Novartis Investigative Site Recruiting Madrid, Spain, 28034 Novartis Investigative Site Recruiting Malaga, Spain, 29010 United Kingdom Novartis Investigative Site Recruiting London, United Kingdom, W1G 6AD Less <<
NCT01553851 Neoplasms, Oral|Mouth Neoplasm... More >>s Less << PHASE2 COMPLETED 2025-12-15 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT03668431 Metastatic Colorectal Cancer Phase 2 Recruiting March 1, 2021 United States, Massachusetts ... More >> Massachusetts General Hosital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Ryan Corcoran, MD    617-724-4000       Principal Investigator: Ryan Corcoran, MD          Dana Farber Cancer Institite Recruiting Boston, Massachusetts, United States, 02215 Contact: Marios Giannakis, MD    617-632-3000    MGIANNAKIS@PARTNERS.ORG    Principal Investigator: Marios Giannakis, MD Less <<
NCT03076164 Lung Adenocarcinoma ... More >> Lung Cancer Lung Cancer Metastatic Lung Cancer Stage IV Recurrent Lung Adenocarcinoma Recurrent Lung Cancer Less << Phase 1 Phase 2 Recruiting March 2020 United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Helena Yu, MD    646-888-4274       Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Helena Yu, MD    646-888-4274       Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Helena Yu, MD    646-888-4274       United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Helena Yu, MD    646-888-4274       Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Helena Yu, MD    646-888-4274       Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10021 Contact: Helena Yu, MD    646-888-4274       Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Helena Yu, MD    646-888-4274 Less <<
NCT01972347 Melanoma Phase 2 Active, not recruiting May 2022 Australia, New South Wales ... More >> Melanoma Institute Australia North Sydney, New South Wales, Australia, 2060 Less <<
NCT03741101 Neurofibromatosis 1|Child|Neur... More >>ofibroma, Plexiform Less << PHASE2 ACTIVE_NOT_RECRUITING 2024-12-15 Sk?ne University Hospital, Lun... More >>d, 22241, Sweden Less <<
NCT01553851 Neoplasms, Oral|Mouth Neoplasm... More >>s Less << PHASE2 COMPLETED 2025-12-15 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT01958112 Cervical Cancer Phase 2 Terminated(Drug supply) - United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT03190915 Activating RAS Mutation ... More >> Blasts Under 20 Percent of Bone Marrow Nucleated Cells Blasts Under 20 Percent of Peripheral Blood White Cells Juvenile Myelomonocytic Leukemia Monosomy 7 Neurofibromatosis Type 1 NF1 Gene Mutation PTPN11 Gene Mutation Splenomegaly Less << Phase 2 Recruiting December 30, 2020 -
NCT03085056 Anaplastic Thyroid Cancer Early Phase 1 Recruiting March 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Eric Sherman, MD    646-888-4234       Contact: David Pfister, MD    646-888-4237       Principal Investigator: Eric Sherman, MD Less <<
NCT03340506 Melanoma Non ... More >>Small Cell Lung Cancer Solid Tumor Rare Cancers High Grade Glioma Less << Phase 4 Recruiting July 17, 2023 United States, Arizona ... More >> Honor Health Research Institute Recruiting Scottsdale, Arizona, United States, 85258 Contact: Kristina Will    623-238-7671    Kristina.Will@honorhealth.com    Principal Investigator: Michael Gordon          United States, Ohio James Cancer Hospital & Solove Research Institute-Ohio State Recruiting Columbus, Ohio, United States, 43210 Contact: Tomasina Wall    614-366-7421    Tomasina.Wall@osumc.edu    Principal Investigator: Kari L. Kendra          United States, Texas Mary Crowley Research Center Recruiting Dallas, Texas, United States, 75251 Contact: Christy Lacy    214-658-1941    clacy@marycrowley.org    Principal Investigator: Minal Barve          France Novartis Investigative Site Recruiting Paris, France, 75970 Spain Novartis Investigative Site Recruiting Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Recruiting Madrid, Spain, 28040 Novartis Investigative Site Recruiting Madrid, Spain, 28050 Less <<
NCT01941927 Melanoma Phase 2 Unknown May 2016 United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, New York Memorial Sloan-Kettering Cancer Center New York City, New York, United States, 10065 Less <<
NCT03516214 Bronchial Neoplasms Phase 1 Recruiting November 25, 2021 Germany ... More >> University Hospital of Aachen Recruiting Aachen, Germany Contact: Christian Hasenbank    +49 241 80 85490    chasenbank@ukaachen.de    University Hospital of Cologne Recruiting Cologne, Germany Contact: Claudia Wömpner    +49 221 478 84556    claudia.woempner@uk-koeln.de    Contact: Gregor Zadoyan, Dr.    +49 221 478 98766    gregor.zadoyan@uk-koeln.de    University Hospital Essen Recruiting Essen, Germany Contact: Diana Cortés Incio    +49 201 723 3155    diana.cortes-incio@uk-essen.de    University Hospital Frankfurt Not yet recruiting Frankfurt, Germany Contact: Anne Oehler    +49 69 6301 86431    ohler@med.uni-frankfurt.de    University Hospital Würzburg Not yet recruiting Würzburg, Germany Spain Hospital Germany Trias y Pujol Not yet recruiting Badalona, Spain Vall d'Hebron University Hospital Not yet recruiting Barcelona, Spain Less <<
NCT03428126 Malignant Neoplasms of Digesti... More >>ve Organs Colorectal Cancer Colon Cancer Less << Phase 2 Enrolling by invitation November 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02939846 Cancer PHASE1 WITHDRAWN 2025-12-18 -
NCT03232892 Non-small Cell Lung Cancer PHASE2 TERMINATED 2019-09-11 University of California, San ... More >>Francisco, San Francisco, California, 94115, United States Less <<
NCT03087448 Non-small Cell Lung Cancer Phase 1 Phase 2 Recruiting March 2021 United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94115 Less <<
NCT03363217 Low-grade Glioma|Plexiform Neu... More >>rofibroma|Central Nervous System Glioma Less << PHASE2 ACTIVE_NOT_RECRUITING 2027-03-01 Alberta Children's Hospital, C... More >>algary, Alberta, T3B 6A8, Canada|Children and Women's Health Centre of British Colombia, Vancouver, British Columbia, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada|CHU Sainte-Justine, Montreal, Quebec, H3T 1C5, Canada|Montreal Children's Hospital, Montreal, Quebec, H4A 3J1, Canada|CHU de Québec, Quebec City, Quebec, G1V 4G2, Canada Less <<
NCT03299088 KRAS Gene Mutation ... More >> Metastatic Non-Squamous Non-Small Cell Lung Carcinoma Recurrent Non-Squamous Non-Small Cell Lung Carcinoma Stage IV Non-Small Cell Lung Cancer AJCC v7 Less << Phase 1 Recruiting March 1, 2021 United States, California ... More >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Jonathan W. Riess    916-734-7771    jwriess@ucdavis.edu    Principal Investigator: Jonathan W. Riess Less <<
NCT05616923 Rosacea, Erythematotelangiecta... More >>tic Less << PHASE1 COMPLETED 2022-12-31 Samuel S. Stratton VA Medical ... More >>Center, Albany, New York, 12208, United States Less <<
NCT01328106 GNA11 Mutation-positive Metast... More >>atic Melanoma|GNAQ Mutation-positive Metastatic Melanoma|Cancer|Metastatic Uveal Melanoma Less << PHASE2 WITHDRAWN 2025-05-12 -
NCT06582745 Langerhans Cell Histiocytosis PHASE2 RECRUITING 1939-12-01 Cook Children's Health Care Sy... More >>stem, Fort Worth, Texas, 76104, United States Less <<
NCT01467310 Breast Cancer EARLY_PHASE1 COMPLETED 2016-03-21 Lineberger Comprehensive Cance... More >>r Center, Chapel Hill, North Carolina, 27599, United States Less <<
NCT01387204 Cancer PHASE1 COMPLETED 2011-07-18 GSK Investigational Site, Taco... More >>ma, Washington, 98418, United States Less <<
NCT00687622 Solid Tumours PHASE1 COMPLETED 2011-11-08 GSK Investigational Site, Scot... More >>tsdale, Arizona, 85258, United States|GSK Investigational Site, Aurora, Colorado, 80045, United States|GSK Investigational Site, Fort Myers, Florida, 33905, United States|GSK Investigational Site, Ocoee, Florida, 34761, United States|GSK Investigational Site, Las Vegas, Nevada, 89169, United States|GSK Investigational Site, Albany, New York, 12206, United States|GSK Investigational Site, Kettering, Ohio, 45409, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19104, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Dallas, Texas, 75246, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, Norfolk, Virginia, 23502, United States Less <<
NCT01037127 Cancer PHASE2 COMPLETED 2025-01-13 GSK Investigational Site, Los ... More >>Angeles, California, 90024, United States|GSK Investigational Site, Aurora, Colorado, 80045, United States|GSK Investigational Site, New York, New York, 10016, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19104, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Nashville, Tennessee, 37232-6307, United States|GSK Investigational Site, Houston, Texas, 77030-4009, United States|GSK Investigational Site, Westmead, New South Wales, 2145, Australia|GSK Investigational Site, East Melbourne, Victoria, 3002, Australia|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia Less <<
NCT04943224 Histiocytosis PHASE2 RECRUITING 2026-03-30 Mother and Child Institute, Wa... More >>rsaw, Mazovian, 01-211, Poland Less <<
NCT01371487 Cancer PHASE1 COMPLETED 2011-09-30 GSK Investigational Site, Detr... More >>oit, Michigan, 48201, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, San Antonio, Texas, 78229, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.62mL

0.33mL

0.16mL

8.12mL

1.62mL

0.81mL

16.25mL

3.25mL

1.62mL

References

 

Historical Records

Categories